BLAINJECTIONINJECTABLE
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
OGIVRI (trastuzumab-dkst) by Viatris (2) is her2/neu/cerbb2 antagonists [moa]. First approved in 2017.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OGIVRI (trastuzumab-dkst) is a biosimilar monoclonal antibody that targets HER2/neu receptors, blocking growth signals in HER2-positive cancers. It is administered via intravenous injection and works by antagonizing the HER2 pathway to inhibit tumor cell proliferation. This biosimilar replicates the efficacy and safety profile of the reference trastuzumab product.
$0.822MPart D
PeakOGIVRI is in peak lifecycle with modest Part D penetration; commercial teams managing a mature biosimilar portfolio with moderate competitive pressure.
Mechanism of Action
HER2/Neu/cerbB2 Antagonists
Pharmacologic Class:
HER2/neu Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
OGIVRI roles are concentrated in commercial, payer relations, and market-access functions rather than research and development. This product offers career opportunities in mature-market biosimilar strategy, healthcare economics, and competitive positioning—ideal for professionals focused on value demonstration and market penetration in oncology.
Brand Manager
Worked on OGIVRI at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.